Generated by AI
Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates. Its current programs address a range of serious conditions across oncology and immunology, such as non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, systemic lupus erythematosus, and rheumatoid arthritis. Cullinan Therapeutics works to advance differentiated drug candidates through early- and mid-stage clinical development, with a business model centered on discovering high-impact molecules and moving them toward proof of concept. Based in Cambridge, Massachusetts, Cullinan Therapeutics plays a role in the biotechnology market as a developer of precision therapies for diseases with significant unmet medical need.
WebsiteOne Main Street
Cambridge, MA, 02142
United States
The latest articles about CGEM.
Hi Tech Motorcars Luxury Collection highlights 2027 Rolls-Royce availability in Austin, including Ghost, Cullinan, and Spectre configurations. C...
Tipranks Press Release.
Summary of Sep 14's posts. Generated by AI.
No summary yet.
Summary of Nov 24's posts. Generated by AI.
Summary of Nov 24's posts. Generated by AI.
Investors talking about CGEM also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.